Paul Choi
Stock Analyst at Goldman Sachs
(0)
# 4657
Out of 5,218 analysts
122
Total ratings
47.27%
Success rate
-17.66%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
PTC Therapeutics | Maintains: Sell | 32 42 | 46.45 | -9.58% | 7 | Dec 4, 2024 | |
Ascendis Pharma | Maintains: Strong Buy | 180 200 | 130.25 | 53.55% | 3 | Sep 17, 2024 | |
Cytokinetics | Downgrades: Neutral | 85 60 | 48.66 | 23.3% | 2 | Aug 13, 2024 | |
Phathom Pharmaceutic... | Maintains: Neutral | 10 12 | 7.87 | 52.48% | 7 | Aug 9, 2024 | |
Dynavax Technologies | Maintains: Neutral | 20 15 | 12.97 | 15.65% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 17 19 | 15.59 | 21.87% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 8 8 | 0.92 | 769.57% | 4 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 38 | 8.27 | 359.49% | 1 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 70 | 19.42 | 260.45% | 1 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 11 18 | 11.35 | 58.59% | 2 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 22 32 | 20.26 | 57.95% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 51 28 | 7.46 | 275.34% | 7 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 2 1 | 0.45 | 122.22% | 6 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 29 50 | 27.5 | 81.82% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 21 19 | 5.32 | 257.14% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 16 2 | 0.33 | 506.06% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 29 26 | n/a | n/a | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 60 | 40.07 | 49.74% | 1 | Dec 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 29 4 | n/a | n/a | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 43 25 | 1.58 | 1482.28% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 450 100 | n/a | n/a | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 4 3 | 2.23 | 34.53% | 7 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 10 4 | 1.04 | 284.62% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 4 | n/a | n/a | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 151 170 | 38.47 | 341.9% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 225 125 | n/a | n/a | 2 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 9 8 | 2.85 | 180.7% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Neutral | 132 | n/a | n/a | 3 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 33 | 17.49 | 88.68% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 112 | 38.38 | 191.82% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 30 | n/a | n/a | 1 | Jan 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 28 | n/a | n/a | 1 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 48 49 | n/a | n/a | 4 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 91 103 | n/a | n/a | 2 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 135 | 126.68 | 6.57% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 240 | n/a | n/a | 2 | Jun 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 5 22 | n/a | n/a | 3 | Apr 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 18 20 | 1 | 1900% | 2 | Mar 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 58 40 | n/a | n/a | 3 | Oct 31, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 60 56 | n/a | n/a | 3 | Aug 6, 2018 |